TEVA vs VTRS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: VTRS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. TEVA and VTRS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined TEVA and VTRS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Teva Pharmaceutical Industries is a global pharmaceutical company and one of the largest generic-drug manufacturers in the world, headquartered in Israel and listed in the US as an ADR. Its business has two broad pillars: a large, mature generics and biosimilars operation that supplies affordable versions of off-patent medicines across many markets, and a growing innovative (branded specialty) portfolio concentrated in neuroscience and respiratory conditions. Key branded products include AUSTEDO for movement disorders such as tardive dyskinesia and Huntington's chorea, UZEDY, a long-acting injectable for schizophrenia, and AJOVY for migraine prevention. Teva also runs an active pharmaceutical ingredients business and a biosimilars program targeting hundreds of millions in revenue by 2027.

Full TEVA guide

Viatris was created in November 2020 by merging Mylan with Pfizer's Upjohn business, uniting a large generics and biosimilars operation with a portfolio of well-known, off-patent branded drugs such as Lipitor, Norvasc, Viagra, and EpiPen. It sells across more than 165 countries and reports through a global commercial footprint that spans developed and emerging markets, with a business mix of generics, established brands, and a smaller but growing specialty and pipeline component. Because most of its revenue comes from mature, off-patent medicines, Viatris behaves like a value stock: steady cash generation, a modest valuation multiple, and slow top-line growth rather than the rapid expansion of a patent-protected innovator.

Full VTRS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• TEVA drivers: Innovative neuroscience growth engine; Pivot to Growth and deleveraging.
• VTRS drivers: Cash flow, debt reduction, and the dividend; Pivot from generics giant to specialty and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Teva carries meaningful risks despite the improving story. For VTRS, the biggest risk is structural: most of Viatris's revenue comes from mature, off-patent medicines facing constant price erosion and competition, which has produced years of flat-to-declining sales and makes growth hard to generate.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick TEVA if you believe its drivers more; VTRS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the TEVA and VTRS guides.

TEVA. These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. Teva trades largely on the credibility of its turnaround, so the market weighs innovative-product momentum and debt reduction more than any single quarter's headline number. Because reported (GAAP) results can be distorted by litigation charges, impairments, and amortization, investors often focus on adjusted metrics; compare both, and confirm current leverage and guidance directly from company filings.

VTRS. Figures are approximate and tied to the asOf date; verify live numbers (current revenue, guidance, adjusted and GAAP EPS, dividend, and debt levels) before acting. Viatris trades on a low multiple typical of a slow-growth value stock, and its adjusted EPS looks much healthier than its GAAP result because large non-cash impairments hit the reported bottom line. The gap between adjusted and GAAP earnings, plus how much of the low multiple reflects genuine value versus stagnant revenue, is the crux of the debate on the stock.

Headline figures (approximate, Jul 2026): TEVA shows quarterly revenue (q1 2026) Roughly $4 billion, ahead of expectations, adjusted (non-gaap) eps (q1 2026) Modest and up low-single-digits year over year, beating consensus, innovative portfolio growth Strong, up roughly 40% year over year, led by AUSTEDO, profitability targets Management targets around a 30% operating margin under Pivot to Growth; VTRS shows revenue (fy2025) ~$13.9 to $14.3 billion, down from ~$14.7 billion in 2024, partly due to divestitures, fy2026 revenue guidance ~$14.45 to $14.95 billion (reaffirmed), fy2026 adjusted eps guidance ~$2.33 to $2.47, fy2025 gaap result Large net loss (~$3.5 billion) driven mainly by non-cash goodwill impairment.

TEVA and VTRS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined TEVA and VTRS exposure against your real portfolio. It is not an investment adviser.